POLYMORPHISM OF INTERLEUKIN 15

IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

Debora Shinta Liana, Andi Cahyadi, Maria Christina Shanty Larasati, Mia Ratwita Andarsini,
I Dewa Gede Ugrasena, Bambang Permono
Department of Child Health, Facutly of Medicine,
Airlangga University/Dr.Soetomo Hospital, Surabaya-Indonesia

BACKGROUND METHODS
 High expression of IL15 has been known correlate
Design Cross sectional study
with CNS impairment and organ infiltration in ALL
cases. Duration March-November 2014
 There are two SNPs of IL15 (rs17007695 and Subject Children aged 1-18 years with ALL
rs10519612) that observed as risk of Adult ALL in and treated with chemoterapy of
Chinese and Egypt population. Indonesian ALL protocol 2013.
 The initial response to remission induction of Method Genotyping analysis by PCR-RFLP
chemotherapy can predict long-term outcome of with BspT104 as restriction enzyme
leukemia.
Independent SNPs rs17007695
OBJECTIVE variable SNPs rs10519612
To analyze association between SNPs IL15 and Dependent Outcome post induction phase:
outcome in children with ALL after induction variable Remission
chemotherapy phase. Non remission
Died
RESULT
Analysis data Chi Square test, Fisher exact test
87 patients enrolled with
ALL Table 1. Characteristic of Subjects

Exclusion : 2 patients with

CHARACTERISTIC NO %
10 patients drop out: Sex
Down Syndrome 9 patients withdrawl
1 patien continue therapy Male 43 58,9
to another hostpital Female 30 41,1
Age
73 patients eligible for this <1 year 1 1,4
study 1 - 10 year 63 86,3
>10 year 9 12,3
WBC count
37 patients with 36 patients with ≤50.000/mm3 53 72,6
standar risk high risk >50.000/mm3 20 27,4
Hemoglobin
23 6 patients 5 16 3 patients Hb <7,0 g/dL 16 21,9
17 patients
patients non patients patients non
died Hb ≥7,0 g/dL 57 78,1
remission remission died remission remission
Platelet
Figure 1. Subject enrolled to the study
<20.000/mm3 12 16,4
Table 2. Genotype distribution of SNPs IL15 and association with patient ≥20.000/mm3 61 83,6
outcome after incution chemotherapy Lymphoblast
Patient Outcome P morphology
Remission Non Died L1 68 93,2
SNPs IL15
N (%) remission N (%) L2 5 6,8
N (%) Risk Stratification
All rs17007695 Standar Risk 37 50,6
subjects CC 26 (63,4) 4 (9,8) 11(26,8) High Risk 36 49,4
TC 13 (40,6) 5 (15,6) 14 (43,8) 0,153
rs10519612
AA 24 (52,2) 6 (13,0) 16 (34,8)
AC & CC 15 (55,6) 3 (11,1) 9 (33,3) 0,952
AC 26 AC
SNP rs10519612
CC 1 CC
Standart rs17007695
46AAAA
risk CC 12 (60,0) 3 (15,0) 5 (25,0)
TC 11 (64,8) 3 (17,6) 3 (17,6) 0,899
rs10519612 32
TC TC
AA 13 (56,5) 4 (17,4) 6 (26,1)
SNP rs17007695 CC CC
41
AC & CC 10 (71,4) 2 (14,3) 2 (14,3) 0,713
0 TT
High risk rs17007695
CC 14 (66,7) 1 (4,8) 6 (28,6)
TC 2 (13,3) 2 (13,3) 11 (73,3) 0,003* 0 20 40 60
rs10519612
AA 11 (47,8) 2 (8,7) 10 (43,5) Heterozygote Homozygote (mutant) wild type
AC & CC 5 (38,5) 1 (7,7) 7 (53,8) 0,871
Figure 2. Distribution of SNPs Il15
CONCLUSION
There is association between SNPs IL15 (rs17007695) and outcomes of childhood ALL after induction chemotherapy
phase in high risk ALL group.
Keyword: ALL. Childhood, IL15,SNPs, Patient outcome